0 Replies
Silence Therapeutics plc will be presenting at the upcoming Symposium on Nucleic Acids as Diagnostics and Therapeutics (Wednesday 14th of December 2011, Royal Society of Chemistry, Burlington House, London, UK). Dr. Klaus Giese will summarise the development of Atu027, Silence’s lead product which is currently in a Phase I clinical... Contine Reading & Discuss→
0 Replies
London, September 21, 2011 - Silence Therapeutics plc (AIM: SLN) (“Silence”, the “Group” or the “Company”), a leading global RNA interference (RNAi) therapeutics company, today announces the appointment of Tony Sedgwick PhD, FRCPath as Chief Business Officer with immediate effect. Dr Sedgwick will be based in Silence’s London office and lead... Contine Reading & Discuss→
